Hangzhou’s Attractions Play Big Part In New Pfizer China Investment
This article was originally published in PharmAsia News
The Hangzhou Economic Development Area has become a highly attractive spot for global pharmas to establish an expanded presence in China, as its integrated platforms, high quality talent pool and incentives help develop a powerhouse of high-end manufacturing. Pfizer’s $350m decision to join the industrial cluster for a new biotech center follows on from others including MSD, Lilly and Bayer.
Register for our free email digests: